Alison A McCormick

Summary

Affiliation: Touro University
Country: USA

Publications

  1. ncbi Genetically engineered Tobacco mosaic virus as nanoparticle vaccines
    Alison A McCormick
    Touro University of California, College of Pharmacy, Vallejo, CA 94592, USA
    Expert Rev Vaccines 7:33-41. 2008
  2. ncbi Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
    Mark L Smith
    Large Scale Biology Corporation, Vacaville, CA 95688, USA
    Virology 348:475-88. 2006
  3. ncbi Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig
    Alison A McCormick
    Large Scale Biology Corporation, Vacaville, CA 95688, USA
    J Immunol Methods 278:95-104. 2003
  4. ncbi Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes
    Kenneth E Palmer
    Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688, USA
    Vaccine 24:5516-25. 2006
  5. ncbi TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models
    Alison A McCormick
    Large Scale Biology Corporation, Vaccine Development, Vacaville, CA 95688, USA
    Vaccine 24:6414-23. 2006
  6. ncbi Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection
    Alison A McCormick
    Large Scale Biology Corporation, 3333 Vacavalley Parkway, Suite 1000, Vacaville, California 95688, USA
    Bioconjug Chem 17:1330-8. 2006
  7. ncbi Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens
    Mark L Smith
    Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Suite 1000, Vacaville, CA 95688, USA
    Virology 358:321-33. 2007

Collaborators

  • Gregory P Pogue
  • Mark L Smith
  • Kenneth E Palmer
  • John A Lindbo
  • Tina Corbo
  • Jacqueline Bernales
  • Terri I Cameron
  • Kathleen M Hanley
  • Sarah A Doucette
  • Tiffany Foster
  • Long V Nguyen
  • Amanda B Lasnik
  • Paul M Brosio
  • Stephan Dillard-Telm
  • Neil D Christensen
  • Michael McCulloch
  • Ann Benko

Detail Information

Publications7

  1. ncbi Genetically engineered Tobacco mosaic virus as nanoparticle vaccines
    Alison A McCormick
    Touro University of California, College of Pharmacy, Vallejo, CA 94592, USA
    Expert Rev Vaccines 7:33-41. 2008
    ..Lastly, we describe how TMV self-assembly properties are being used to make a new mammalian RNA pseudovirus, that has unique characteristics for RNA and protein antigen delivery to antigen-presenting cells...
  2. ncbi Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
    Mark L Smith
    Large Scale Biology Corporation, Vacaville, CA 95688, USA
    Virology 348:475-88. 2006
    ..By demonstrating the presentation of whole proteins, this study expands the utility of TMV as a vaccine scaffold beyond that which is possible by genetic manipulation...
  3. ncbi Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig
    Alison A McCormick
    Large Scale Biology Corporation, Vacaville, CA 95688, USA
    J Immunol Methods 278:95-104. 2003
    ..Four out of four anti-scFv sera were also shown to recognize the Ig on human tumor cells by flow cytometry analysis...
  4. ncbi Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes
    Kenneth E Palmer
    Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688, USA
    Vaccine 24:5516-25. 2006
    ..Finally, the study demonstrated that rTMV were excellent agents for the induction of strong protection in a pre-clinical disease model of papillomavirus infection...
  5. ncbi TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models
    Alison A McCormick
    Large Scale Biology Corporation, Vaccine Development, Vacaville, CA 95688, USA
    Vaccine 24:6414-23. 2006
    ..7-Ova and B16 melanoma models. From these results we conclude that TMV was an effective antigen carrier for inducing cellular immune responses to less than 1 microg of peptide...
  6. ncbi Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection
    Alison A McCormick
    Large Scale Biology Corporation, 3333 Vacavalley Parkway, Suite 1000, Vacaville, California 95688, USA
    Bioconjug Chem 17:1330-8. 2006
    ..Interestingly, different bivalent vaccine formulations were required to improve vaccine efficacy for Ova or melanoma tumor model systems...
  7. ncbi Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens
    Mark L Smith
    Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Suite 1000, Vacaville, CA 95688, USA
    Virology 358:321-33. 2007
    ..The SFV vector/TMV CP system described provides an alternative nucleic acid delivery mechanism that is safe, easy to manufacture in vitro and that also facilitates the generation of unique nucleic acid/protein antigen compositions...